

Coexpression of a $\text{Ca}_v1.2$ protein lacking an N-terminus and the first domain specifically suppresses L-type calcium channel activity

Tatsuhiko Ebihara^{a,*}, Yuriko Komiya^b, Hiroko Izumi-Nakaseko^{a,c}, Satomi Adachi-Akahane^b, Shigeo Okabe^{a,d}, Yasushi Okamura^{a,e}

^aMolecular Neurophysiology Group, Neuroscience Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan

^bLaboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan

^cDepartment of Advanced Medical Science, Institute of Medical Science University of Tokyo, Minato-ku, Tokyo 108-8639, Japan

^dDepartment of Anatomy and Cell Biology, School of Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan

^eDepartment of Developmental Neurophysiology, Center for Integrative Bioscience, Okazaki National Research Institutes, Okazaki 444-8585, Aichi, Japan

Received 16 August 2002; accepted 26 August 2002

First published online 6 September 2002

Edited by Maurice Montal

Abstract L-type Ca^{2+} channels play a critical role in many types of cells, including nerve, muscle and endocrine cells. The most popular and effective tools for analyzing the roles of L-type calcium channels (L-channels) are specific antagonists such as dihydropyridines. With these drugs however, it is difficult to target specific cells. One solution is to develop a genetically targetable inhibitor coded by DNA. As a candidate for such an inhibitor, a dominant negative mutant of $\text{Ca}_v1.2$ was designed by mimicking an ascidian 3-domain-type $\alpha1$ subunit (that inhibits the full-length subunit's current). The 3-domain-type $\text{Ca}_v1.2$ subunit significantly inhibited wild-type $\text{Ca}_v1.2$ current, but not other ionic currents such as $\text{Ca}_v2.1$ and Na_v channels in *Xenopus* oocyte expression systems. Western blot analysis showed that the expression of the wild-type protein into the plasma membrane was significantly suppressed on coexpression with the truncated protein. These findings support that an N-terminus-truncated mutant could serve as a specific genetically encoded inhibitor for L-channels.

© 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

Key words: Calcium channel; L-type; Truncation; Specific inhibition; *Xenopus* oocyte

1. Introduction

L-type voltage dependent calcium channels are distributed broadly [1,2], and have many roles in cell functions [3], including gene expression [4–6], learning and memory [7]. There are specific drugs for L-type calcium channels (L-channels) such as dihydropyridine, phenylalkylamines [8] and FPL64176 [9]. These reagents serve as important tools to analyze the roles of L-channels. However, L-channels exist in many types of cells. It is therefore difficult to define their roles in vivo using these drugs. Knock out mice of L-channel $\alpha1$ subunit genes have already been reported [10]. However, the knocking out of $\text{Ca}_v1.2$ in mice is fatal. A new method needs to be established to overcome such problems.

We designed here a dominant negative mutant of the L-channel based on a recent finding in the ascidian Ca^{2+} channel; a 3-domain-type variant of the calcium channel $\alpha1$ subunit TuCa1 had a significant inhibitory effect on the expression of the full-length calcium channel current both in a *Xenopus* oocyte expression system and ascidian native cells [11]. Since TuCa1 is closely related to L-channels, we designed a similar deletion in the $\text{Ca}_v1.2$ mutant by referring to this truncated isoform. We found that the 3-domain-type $\text{Ca}_v1.2$ ($\Delta\text{Ca}_v1.2$) mutant has a strong inhibitory effect on the wild-type $\text{Ca}_v1.2$ channel current. This inhibition was specific to $\text{Ca}_v1.2$, since it did not affect the current activity of Na_v channels and $\text{Ca}_v2.1$. We thus propose that the dominant negative $\text{Ca}_v1.2$ mutant will serve as a useful molecular tool for future studies on L-type Ca^{2+} channels.

2. Materials and methods

2.1. DNA construction

For optimizing translation, KOZAK core sequence [12] was inserted just before the first Met of the $\alpha1$ subunits.

A full-length $\text{Ca}_v1.2$ cDNA [13] was subcloned into a *Xenopus* expression vector, pSD64TR, at *KpnI* and *NotI* sites. $\Delta\text{Ca}_v1.2$ was designed as in Fig. 1. The 5'-side was amplified using Pfu polymerase (Stratagene) and was joined to the 3'-part of the $\text{Ca}_v1.2$ subunit at the *EcoRI* site. A stop codon was introduced into the 3-domain-type mutant (stop $\Delta\text{Ca}_v1.2$), as shown in Fig. 4a. A DNA fragment around first Met and stop codon was obtained using Pfu polymerase and joined to the 3' DNA fragment of $\text{Ca}_v1.2$.

The 5'-regions containing putative initial methionines of both the full-length and $\Delta\text{Ca}_v2.1$ cDNA were amplified by Pfu polymerase, were connected to the 3' part of the $\text{Ca}_v2.1$ subunit at the *HindIII* site, and were subcloned into pSD64TR at *KpnI* and *EcoRV* sites.

2.2. RNA injection for *Xenopus* oocytes

Plasmids containing channel subunit cDNA were linearized with *SalI* (most of cDNAs) or *NotI* ($\beta2b$ and $\text{Na}_v1.4$) and transcribed with SP6 (most of cDNAs) or T7 ($\beta2b$) RNA polymerase for injection into *Xenopus* oocytes.

Xenopus oocytes were prepared as described [14]. Synthetic RNA of $\alpha1$ subunits was injected into an oocyte at a concentration of 0.25 ng/nl. $\beta2b$ and $\alpha2\delta$ subunits of the rabbit Ca^{2+} channel were simultaneously injected at 0.25 ng/nl. In the experiments of coexpression with $\text{Na}_v1.4$ RNA, concentrations were 0.15 ng/nl $\mu1$, 0.2 ng/nl $\alpha1$, $\beta2b$ and $\alpha2\delta$. RNA concentrations were modified as shown in the figure legends. The volume of RNA solution injected into each oocyte was 50 nl. Injected oocytes were cultured at 18°C. The amount of cRNA

*Corresponding author. Fax: (81)-298-61 6406.
E-mail address: t.ebihara@aist.go.jp (T. Ebihara).

was roughly adjusted based on the concentration estimated by ethidium bromide staining following RNA electrophoresis. All cRNA injections contained $\beta 2b$ and $\alpha 2\delta$. Oocytes from the same batch were recorded within about 5 h between 2 and 4 days after injection.

2.3. Electrophysiology of *Xenopus* oocytes

Electrical recordings of *Xenopus* oocytes were made as described in [11].

The solutions used for recording Ba^{2+} currents consisted of 20 mM $Ba(OH)_2$, 35 mM NaOH, 77 mM methanesulfonate, 2 mM KOH, and 5 mM HEPES (pH 7.4); or 5 mM $Ba(OH)_2$ and 65 mM NaOH. The solution for recording Na^+ currents consisted of 96 mM NaCl, 1 mM $MgCl_2$, 2 mM KCl and 5 mM HEPES (pH 7.4). Linear leaks were determined by measuring holding currents. Recordings with large leakages (> 200 nA at -70 mV) were discarded. Results are presented as the mean \pm S.E.M. (error bars in the figures).

2.4. Transient expression of $Ca_v1.2$ subunits in BHK6 cells

Full-length and $\Delta Ca_v1.2$ were transiently expressed in BHK6 cells [15]. Cell cultures and DNA transfections were carried out as described in [16].

2.5. Whole-cell patch clamp recording

The whole-cell L-type channel currents were recorded with 2 mM Ca^{2+} or 10 mM Ba^{2+} as a charge carrier in a bath solution containing 137 mM NaCl, 5.4 mM KCl, 1 mM $MgCl_2$, 10 mM glucose, 10 mM HEPES, and 2 mM $CaCl_2$ (pH 7.4) at room temperature. The resistance of the microelectrodes ranged from 1.5 to 4 M Ω when filled with 110 mM cesium methanesulfonate, 20 mM TEA, 14 mM EGTA, 5 mM MgATP, 5 mM disodium creatine phosphate, 0.2 mM GTP, and 10 mM HEPES (pH 7.3). Currents were measured as described in [16]. Results are presented as the mean \pm S.E.M. Statistical significance was assessed with the Student–Welch unpaired *t*-test. Differences at $P < 0.05$ were considered to be significant.

2.6. Western blotting

At 36 h after transfection, cells cultured in 35 mm dishes were incubated on ice for 5 min by replacing with 180 μ l of Triton X-100 buffer containing 10 mM Tris–Cl (pH 7.4), 5 mM EGTA, 5 mM EDTA, 120 mM NaCl, 1% (or 0.1%) Triton X-100, 200 nM PMSF, 2 μ M leupeptin, and 3 μ M pepstatin A. Cells were then mixed and incubated on ice for 5 min. Cell lysates were separated by spinning. Supernatant (150 μ l) was added to 4 \times SDS loading buffer (50 μ l). The pellet was added to 1% Triton X-100 buffer (180 μ l) and 4 \times SDS loading buffer (60 μ l) and incubated at 37°C for 20 min, then loaded for SDS–PAGE. The rabbit polyclonal antibody CT4 was made to target the C-terminal (aa 2027–2143) of the $Ca_v1.2$ subunit.

3. Results

3.1. $\Delta Ca_v1.2$ inhibited functional expression of full-length $Ca_v1.2$

To make a $Ca_v1.2$ dominant negative mutant, we referred to the sequence of the ascidian calcium channel (Fig. 1). Our previous study showed that a truncated variant of the ascidian L-type-like Ca^{2+} channel TuCa1 starting from the second

TuCa1	WLTLAQDLANKILLTFTIEMLVKMYSLGMQQYFVSLFNRFDCF
$\Delta NTuCa1$	IIS2 MLVKMYSLGMQQYFVSLFNRFDCF
	*
$\Delta Ca_v1.2$	WLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCF
	*
$\Delta Ca_v2.1$	WLSDFLYAAEFIFLGLFMSEMFIMYGLGTRPYFHSSFNCFDCG

Fig. 1. Peptide sequences of ascidian (TuCa1) and mammalian ($Ca_v2.1$, $Ca_v1.2$) calcium channel α_1 subunits around the IIS2 region. $\Delta NTuCa1$ starts from the Met indicated by asterisks. Other mutants were designed to start from the same position.




Fig. 2. Biophysical studies of suppressive effect by $\Delta Ca_v1.2$ in *Xenopus* oocytes. $\Delta Ca_v1.2$ significantly reduces expression of $Ca_v1.2$. a: Representative traces of Ba^{2+} currents from oocytes injected with each combination of cRNA as indicated. b: I–V relations of Ba^{2+} currents from cells only expressing $Ca_v1.2$ (triangle; $n = 7$), those co-expressing $Ca_v1.2$ and $\Delta Ca_v1.2$ (rectangle; $n = 7$) and those only expressing auxiliary subunits (circle; $n = 6$). c: Comparison of maximum amplitudes of Ba^{2+} currents among oocytes expressing various combinations of subunits.

domain IIS2 works as the suppressor of functional expression of the full-length protein. We suspected that a similar deleted form of mammalian Ca_v channel may exhibit such inhibition. We thus made a 3-domain-type α_1 mutant starting from the corresponding Met (Fig. 1, asterisked Met).

To test the inhibitory effect of the $\Delta Ca_v1.2$ and $\Delta Ca_v2.1$, full-length α_1 cRNAs were coexpressed with or without 3-domain-type mutants. $\Delta Ca_v1.2$ inhibited almost completely the wild-type $Ca_v1.2$, while $\Delta Ca_v2.1$ had no effect on $Ca_v1.2$ (Fig. 2). On the other hand, $\Delta Ca_v1.2$ had no strong inhibitory activity against the P/Q-type calcium channel subunit $Ca_v2.1$ (Fig. 2a,c). The experiments were repeated four times using other batches of oocytes and similar results were obtained.

3.2. General translation was normal during the inhibition of Ca_v currents by truncated mutants

To test the possibility that the combination of $Ca_v1.2$ and $\Delta Ca_v1.2$ has a strong inhibitory effect on general protein synthesis in *Xenopus* oocytes, we examined the Na^+ channel current derived from the rat $Na_v1.4$ gene when either coexpressed or not with $Ca_v1.2$ channel subunits. At 20 ms depolarization, Na^+ current traces were similar among cells injected with $Na_v1.4$ channel $Na_v1.4$ only, with $Na_v1.4$ plus $Ca_v1.2$, and with $Na_v1.4$, $Ca_v1.2$ plus $\Delta Ca_v1.2$ (Fig. 3), suggesting that $\Delta Ca_v1.2$ does not suppress general translation in oocytes. The experiments were repeated twice using other batches with similar results.

3.3. Inhibition by $\Delta Ca_v1.2$ occurred after translation

It is possible that $\Delta Ca_v1.2$ inhibits $Ca_v1.2$ expression




Fig. 3. Absence of inhibition of sodium channel expression. a: Representative traces of $\text{Na}_v1.4$ Na^+ currents from *Xenopus* oocytes. b: Comparison of maximum amplitudes of Na^+ currents.




Fig. 4. cRNA having a stop codon just after the first Met did not inhibit $\text{Ca}_v1.2$ channel current. a: N-terminal DNA sequence of $\Delta\text{Ca}_v1.2$. A point mutation (lower 'A') was introduced. b: Maximum amplitudes of Ba^{2+} currents among oocytes. Concentrations of injected cRNAs were, 0.2 ng/nl for $\text{Ca}_v1.2$, and 0.3 ng/nl for stop $\Delta\text{Ca}_v1.2$ and $\Delta\text{Ca}_v1.2$.

through RNA–RNA interaction. Alternatively, it may have an inhibitory effect at the protein level. To distinguish between these two possibilities, we introduced a stop codon into $\Delta\text{Ca}_v1.2$ just after the initial Met (Fig. 4a), retaining all the downstream sequence of $\Delta\text{Ca}_v1.2$ (stop $\Delta\text{Ca}_v1.2$). Stop $\Delta\text{Ca}_v1.2$ did not exhibit an inhibitory effect like $\Delta\text{Ca}_v1.2$ (Fig. 4b). This indicates that inhibition by $\Delta\text{Ca}_v1.2$ should occur at a step after the translation, not at the RNA level.

3.4. $\Delta\text{Ca}_v1.2$ prevented the full-length protein from appearing in membrane fractions

To gain insight into the molecular mechanism of inhibition by $\Delta\text{Ca}_v1.2$, we used a transient DNA transfection system. We utilized a mammalian cell line (BHK-6 cells) instead of *Xenopus* oocytes for this experiment, because we could not reliably detect $\text{Ca}_v1.2$ protein from *Xenopus* oocyte by Western blot analysis. First, we checked whether inhibition of the full-length channel activity by $\Delta\text{Ca}_v1.2$ also occurs in BHK-6 cells, which stably express rabbit $\beta1a$ and $\alpha2\delta$ subunits. Patch clamp recordings showed that coexpression with $\Delta\text{Ca}_v1.2$ markedly reduced the amount of current derived from the full-length $\text{Ca}_v1.2$ (Fig. 5a,b). By Western blotting of the Triton X-100 soluble fraction of cells of the same batches used for electrophysiology, $\text{Ca}_v1.2$ immunoreactivity was shown to be greatly reduced on coexpression with $\Delta\text{Ca}_v1.2$. This inhibition seemed dose-dependent: three times more $\Delta\text{Ca}_v1.2$ significantly reduced the immunoreactivity of the full-length $\text{Ca}_v1.2$. Unexpectedly, the immunoreactivity of $\Delta\text{Ca}_v1.2$ was much weaker than the band of full-length $\text{Ca}_v1.2$ even though $\Delta\text{Ca}_v1.2$ was transfected with a three-fold excess of DNA (Fig. 5c). In addition, the immunoreactivity of $\Delta\text{Ca}_v1.2$ in




Fig. 5. The suppression of Ca^{2+} channel activity and protein expression by $\Delta\text{Ca}_v1.2$ in BHK6 cells. a: Coexpression of $\Delta\text{Ca}_v1.2$ caused significant suppression of L-channel current. Representative traces recorded from cells transfected with DNAs as indicated. Ca^{2+} channel current traces were recorded with 2 mM Ca^{2+} (black) or 10 mM Ba^{2+} (gray). b: Current densities of Ca^{2+} or Ba^{2+} current. Asterisks indicate $P < 0.01$. c: $\Delta\text{Ca}_v1.2$ suppressed the expression of $\text{Ca}_v1.2$. BHK6 cells were transfected with $\text{Ca}_v1.2$ plus pcDNA3 or $\Delta\text{Ca}_v1.2$ at a molar ratio of 1:1 or 1:3. Soluble fractions of cell lysates were analyzed with anti-CT4 antibody. d: Low solubility of $\Delta\text{Ca}_v1.2$. BHK6 cells indicated by Western blot, transfected as indicated at a molar ratio of 1:3, were harvested. Triton X-100 soluble (S) and insoluble (I) fractions were analyzed with anti- $\text{Ca}_v1.2$ CT4 antibody. A non-specific band slightly overlapped the signal for $\Delta\text{Ca}_v1.2$ in the soluble fraction (c,d). Note that the increased intensity of the band on transfection of $\Delta\text{Ca}_v1.2$ which indicates the presence of $\Delta\text{Ca}_v1.2$.




Fig. 6. $\Delta\text{Ca}_v2.1$ mutant did not work as a dominant negative mutant. a: Representative traces of Ba^{2+} currents from *Xenopus* oocytes. b: Comparison of maximum amplitudes of Ba^{2+} currents. The cRNA concentration is modified as 0.15 ng/nl for $\text{Ca}_v2.1$, 0.15 ng/nl or 0.45 ng/nl for $\Delta\text{Ca}_v2.1$, 0.15 ng/nl for $\beta 2b$ and 0.15 ng/nl for $\alpha 2\delta$.

cells transfected with $\Delta\text{Ca}_v1.2$ alone was less than that of $\text{Ca}_v1.2$ (data not shown). To check the possibility that $\Delta\text{Ca}_v1.2$ is expressed in the insoluble fraction, we harvested the cells on altering Triton X-100 concentrations, and analyzed $\text{Ca}_v1.2$ channel immunoreactivity in the insoluble fraction. This analysis indicated that the $\Delta\text{Ca}_v1.2$ subunit tended to exist in the insoluble fraction. The immunoreactivity of the full-length $\text{Ca}_v1.2$ in the soluble fraction decreased when $\Delta\text{Ca}_v1.2$ was coexpressed as already shown (Fig. 5c). In contrast, $\text{Ca}_v1.2$ in the insoluble fraction with 1% Triton X-100 increased when $\Delta\text{Ca}_v1.2$ was coexpressed (Fig. 5d). In the soluble fractions, there was a non-specific band slightly overlapping with the signal for $\Delta\text{Ca}_v1.2$ (Fig. 5c,d). However, the existence of $\Delta\text{Ca}_v1.2$ was evident from the increased intensity of the band on transfection of $\Delta\text{Ca}_v1.2$, as compared with transfection of the vehicle vector alone.

3.5. $\Delta\text{Ca}_v2.1$ did not act as a dominant negative mutant

To know whether a truncated protein lacking an N-terminus and the first domain of other classes of Ca^{2+} channels also show similar negative effect, we made a similar 3-domain mutant for $\text{Ca}_v2.1$ (Fig. 1). However, this mutant caused little inhibition of the full-length $\text{Ca}_v2.1$ current (Fig. 6). There was still no strong inhibition even when three-times excess amount of $\Delta\text{Ca}_v2.1$ cRNA was injected. Similar results were obtained for $\text{Ca}_v3.1$ in HEK cells (data not shown). Therefore, suppression by $\Delta\text{Ca}_v1.2$ may be mediated by mechanisms unique to $\text{Ca}_v1.2$.

4. Discussion

In this study, we designed an inhibitory subunit of $\text{Ca}_v1.2$ by mimicking an endogenous calcium channel subunit of ascidian embryos which strongly suppresses the functional expression of the full-length protein [11]. This subunit ($\Delta\text{Ca}_v1.2$)

significantly inhibited $\text{Ca}_v1.2$ channel current in a subtype-specific manner (Fig. 2). Moreover, the inhibition by $\Delta\text{Ca}_v1.2$ had no effect on the expression of the Na^+ channel (Fig. 3), indicating that it is not mediated by inhibition of the general translational machinery. Since the insertion of a premature stop codon into $\Delta\text{Ca}_v1.2$ led to a loss of the effect, the inhibition must occur at the protein level (Fig. 4). Western blot analysis indicated that the coexpression of $\Delta\text{Ca}_v1.2$ reduced the expression of full-length $\text{Ca}_v1.2$ in the Triton X-100 soluble fraction (including the plasma membrane) (Fig. 5). A similar deletion construct for another class of calcium channel, $\text{Ca}_v2.1$ however, had no strong inhibitory effect on the full-length $\text{Ca}_v2.1$ current (Fig. 6), suggesting that inhibition of the full-length-derived current by the 3-domain-type $\alpha 1$ subunit occurs via a mechanism unique to Ca_v1 class channels.

Familial episodic ataxia type 2 is an autosomal dominant paroxysmal cerebral disorder. Some types of this disorder are caused by one base mutation of the $\text{Ca}_v2.1$ gene [17,18]. This mutation results in the translation of a truncated form of $\text{Ca}_v2.1$ consisting of the I, II and a part of the III domain. Recently, truncated subunits consisting of domains I and II or domains III and IV of $\text{Ca}_v2.2$ have been reported to work as dominant negative [19]. $\text{Ca}_v2.2$ mutants are expressed and effect on protein synthesis or protein folding of wild-type channels. In our case, the 3-domain-mutant of $\text{Ca}_v2.1$ and $\text{Ca}_v3.1$ did not show a significant inhibitory effect on wild-type channels. Therefore, the mechanism of 3-domain-mutant of $\text{Ca}_v1.2$ should be different from the other Ca_v dominant negative effects. β -Subunit is needed for the effective expression of current. It is unlikely that $\Delta\text{Ca}_v1.2$ scavenges the β -subunit, because it lacks a β -subunit binding region in the I–II loop [20]. Another line of evidence indicates that this inhibition is subtype-specific: $\Delta\text{Ca}_v1.2$ did not inhibit $\text{Ca}_v2.1$ current.

Truncated K^+ channels often show dominant negative effects. This can be accounted for by inhibition of coassembly or insertion into the plasma membrane [21]. A similar interpretation does not apply to the Ca_v channel however, because a single Ca_v subunit forms a single pore. Nevertheless, suppression of the full-length protein by $\Delta\text{Ca}_v1.2$ suggests that some cooperative interaction among homogenous channels is required for efficient channel assembly or expression. Immunostaining analysis revealed that L-channels are clustered in cell bodies and proximal dendrites in neurons [22]. Recently, a single channel imaging study of $\text{Ca}_v1.2$ suggested that $\text{Ca}_v1.2$ molecules form clusters as $\alpha 1$ subunit themselves through self-aggregation [23]. These findings are consistent with the above-mentioned idea.

Our $\Delta\text{Ca}_v1.2$ mutant inhibits specifically $\text{Ca}_v1.2$ channel current. Although the mechanisms of suppression require further study, this mutant will be potentially useful for analyzing the roles of L-channels. We are currently making transgenic mice which express this $\Delta\text{Ca}_v1.2$ mutant only in certain types of neurons to better define the role of the L-channel in neural development and function.

Acknowledgements: We thank Dr. T. Snutch for kindly providing a cDNA clone of the rat brain $\text{Ca}_v1.2$ subunit, and expression vector pSD64TR, Dr. Y. Mori for a cDNA clone of rabbit $\text{Ca}_v2.1$ and BHK-6 cells, Dr. Flockerzi for cDNA clones of rabbit $\beta 2b$, Dr. T. Tanabe for rabbit $\alpha 2\delta$, and Dr. G. Mandel for rat $\text{Na}_v1.4$.

References

- [1] Mori, Y., Mikala, G., Varadi, G., Kobayashi, T., Koch, S., Wakamori, M. and Schwartz, A. (1996) *Jpn. J. Pharmacol.* 72, 83–109.
- [2] Morgans, C.W. (2001) *Invest. Ophthalmol. Vis. Sci.* 42, 2414–2418.
- [3] Tsien, R.W., Lipscombe, D., Madison, D., Bley, K. and Fox, A. (1995) *Trends Neurosci.* 18, 52–54.
- [4] Hardingham, G.E., Chawla, S., Johnson, C.M. and Bading, H. (1997) *Nature* 385, 260–265.
- [5] Finkbeiner, S. and Greenberg, M.E. (1998) *J. Neurobiol.* 37, 171–189.
- [6] Bito, H., Deisseroth, K. and Tsien, R.W. (1997) *Curr. Opin. Neurobiol.* 7, 419–429.
- [7] Grover, L.M. and Teyler, T.J. (1990) *Nature* 347, 477–479.
- [8] Ginsberg, M.D., Lin, B., Morikawa, E., Dietrich, W.D., Busto, R. and Globus, M.Y. (1991) *Arzneimittelforschung* 41, 334–337.
- [9] Rampe, D. and Lacerda, A.E. (1991) *J. Pharmacol. Exp. Ther.* 259, 982–987.
- [10] Namkung, Y., Skrypnik, N., Jeong, M.J., Lee, T., Lee, M.S., Kim, H.L., Chin, H., Suh, P.G., Kim, S.S. and Shin, H.S. (2001) *J. Clin. Invest.* 108, 1015–1022.
- [11] Okagaki, R., Izumi, H., Okada, T., Nagahora, H., Nakajo, K. and Okamura, Y. (2001) *Dev. Biol.* 230, 258–277.
- [12] Kozak, M. (1987) *Nucleic Acids Res.* 15, 8125–8148.
- [13] Snutch, T.P., Tomlinson, W.J., Leonard, J.P. and Gilbert, M.M. (1991) *Neuron* 7, 45–57.
- [14] Goldin, A.L. (1992) *Methods Enzymol.* 207, 266–279.
- [15] Wakamori, M., Yamazaki, K., Matsunodaira, H., Teramoto, T., Tanaka, I., Niidome, T., Sawada, K., Nishizawa, Y., Sekiguchi, N., Mori, E., Mori, Y. and Imoto, K. (1998) *J. Biol. Chem.* 273, 34857–34867.
- [16] Yamaguchi, S., Okamura, Y., Nagao, T. and Adachi-Akahane, S. (2000) *J. Biol. Chem.* 275, 41504–41511.
- [17] Ophoff, R.A., Terwindt, G.M., Vergouwe, M.N., van Eijk, R., Oefner, P.J., Hoffman, S.M., Lamerdin, J.E., Mohrenweiser, H.W., Bulman, D.E., Ferrari, M., Haan, J., Lindhout, D., van Ommen, G.J., Hofker, M.H., Ferrari, M.D. and Frants, R.R. (1996) *Cell* 87, 543–552.
- [18] Yue, Q., Jen, J.C., Thwe, M.M., Nelson, S.F. and Baloh, R.W. (1998) *Am. J. Med. Genet.* 77, 298–301.
- [19] Raghieb, A., Bertaso, F., Davies, A., Page, K.M., Meir, A., Bogdanov, Y. and Dolphin, A.C. (2001) *J. Neurosci.* 21, 8495–8504.
- [20] Neuhuber, B., Gerster, U., Mitterdorfer, J., Glossmann, H. and Flucher, B.E. (1998) *J. Biol. Chem.* 273, 9110–9118.
- [21] Tu, L. and Deutsch, C. (1999) *Biophys. J.* 76, 2004–2017.
- [22] Hell, J.W., Westenbroek, R.E., Warner, C., Ahljianian, M.K., Prystay, W., Gilbert, M.M., Snutch, T.P. and Catterall, W.A. (1993) *J. Cell Biol.* 4, 949–962.
- [23] Harms, G.S., Cognet, L., Lommerse, P.H., Blab, G.A., Kahr, H., Gamsjager, R., Spaink, H.P., Soldatov, N.M., Romanin, C. and Schmidt, T. (2001) *Biophys. J.* 81, 2639–2646.